This is a forecasted NIH/NINDS research program to functionally validate new therapeutic targets for Alzheimer's disease-related dementias, structured as a phased R61/R33-style award with about 2 awards from $1,800,000 total. It is for labs and research-driven organizations, including small biotech businesses, that can build disease models and run milestone-based validation studies. If you are not doing biomedical research, do not apply.
| Industry | Estimated fit |
|---|---|
| Healthcare & BiotechDeadline is more than 30 days away | 59 |
| Technology & SoftwareMatches your industry (tech) | 57 |
| Education & TrainingMatches your industry (stem) | 56 |
| Environment & ConservationLimit: Nothing in this notice points to environment & conservation | 54 |
| Energy & Clean TechLimit: Nothing in this notice points to energy & clean tech | 51 |
| Arts & CultureLimit: Nothing in this notice points to arts & culture | 49 |
| Industry | Estimated fit |
|---|---|
| Social Services & NonprofitLimit: Nothing in this notice points to social services & nonprofit | 49 |
| Housing & Real EstateLimit: Nothing in this notice points to housing & real estate | 48 |
| Transportation & LogisticsMatches your industry (transit) | 46 |
| Food & BeverageLimit: Nothing in this notice points to food & beverage | 45 |
| Agriculture & FarmingLimit: Nothing in this notice points to agriculture & farming | 43 |
| Finance & BankingLimit: Nothing in this notice points to finance & banking | 43 |
| ManufacturingLimit: Nothing in this notice points to manufacturing | 42 |
| Retail & E-CommerceLimit: Nothing in this notice points to retail & e-commerce | 42 |
| Construction & InfrastructureLimit: Nothing in this notice points to construction & infrastructure | 39 |
These are our matcher’s estimates for a typical business in each industry. A real match depends on your size, your state and what you need the money for — check your own fit.
NIH/NINDS forecasted phased (R61/R33-style) research award to functionally validate newly identified therapeutic target candidates for Alzheimer's disease-related dementias in in vitro and in vivo models. Eligible applicants include small businesses, for-profit organizations, nonprofits, universities, and state, local, and tribal governments.
The National Institute of Neurological Disorders and Stroke (NINDS) is interested in supporting ambitious research projects that propose comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer’s Disease–Related Dementias (ADRD). A major barrier to the development of effective treatments for ADRD, as well as other complex central nervous system disorders, is the lack of well-validated targets that are clearly linked to disease mechanisms. Successful translation of basic discoveries into the clinic depends on the rigor of target validation and confidence in a causal relationship between modulation of a target and its functional physiological consequences relevant to treating or preventing disease. This initiative aims to de-risk subsequent translational research and accelerate the development of novel therapeutic strategies. NINDS believes that this initiative would be most appropriately supported by a phased award mechanism (for example, R61/R33). In the initial phase, support would be provided for the development of customized technologies, models, and protocols to modulate the expression or activity of candidate targets and to assess their physiological consequences in relevant in vitro and in vivo disease models. Upon successful achievement of predefined, milestone-based technical feasibility and proof-of-concept criteria, projects would transition to the second phase focused on measuring and cross-validating the effects of target modulation across multiple experimental modalities and collaborating laboratories, in accordance with NIH rigor and reproducibility guidelines. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop responsive projects and establish appropriate cross-disciplinary collaborations.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions) are not allowed
Topics
Open opportunities funding similar work, from the same funder or in the same place.
NIH BRAIN Initiative grants to develop tools and computational models for high-resolution, synchronous measurement of complex behaviors alongside neural activity in humans and other species. Eligible applicants include…
NIH/NCI K99/R00 career-development award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent tenure-track faculty positions; requires the candidate to lead an…
NIH/NCI UH3 cooperative agreement to clinically validate established molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, or treatment response using specimens from…
NIH/NCI K99/R00 award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent faculty careers. The applicant is typically the sponsoring institution; eligible…
NIH/NCI cooperative agreement (UH2/UH3) funding validation of molecular, cellular, and imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response. Open to universities,…
NIH/NCI program funding revision applications to adapt and clinically validate molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response prediction.…